TY - JOUR
T1 - Meta-analysis of the likelihood of FOXC2 expression in earlyand late-stage tumors
AU - Kume, Tsutomu
AU - Shackour, Tarek
N1 - Funding Information:
This work was supported by the National Institutes of Health (NIH) (HL 126920 to T. K.). The authors thank W. Kevin Meisner, PhD, ELS, for editorial assistance.
Publisher Copyright:
© Kume et al.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Background: Aberrations in the expression of the transcription factor forkhead box C2 (FOXC2) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC2 and cancer progression by conducting a metaanalysis of studies that reported the frequency of FOXC2 expression in tumors of different stages (T1, T2, T3, T4). Methods: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC2" and "cancer" then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC2 expression via immunohistochemical staining, and assessed the relationship between FOXC2 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 139 studies, 9 of which met all inclusion criteria. A total of 1433 tumor samples were evaluated in the 9 studies; 596 samples were from early-stage (T1-T2) tumors, and 838 were from late-stage (T3-T4) tumors. FOXC2 was expressed in 46.0% of all samples, in 32.4% of early-stage tumor samples, and in 55.6% of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC2 expression in late-stage samples was 1.367 (95% CI = 1.103-1.695, p = 0.004). Conclusion: The results from our meta-analysis of 9 studies indicate that FOXC2 is 36.7% more likely to be expressed in late-stage tumors than in early-stage tumors.
AB - Background: Aberrations in the expression of the transcription factor forkhead box C2 (FOXC2) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC2 and cancer progression by conducting a metaanalysis of studies that reported the frequency of FOXC2 expression in tumors of different stages (T1, T2, T3, T4). Methods: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC2" and "cancer" then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC2 expression via immunohistochemical staining, and assessed the relationship between FOXC2 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 139 studies, 9 of which met all inclusion criteria. A total of 1433 tumor samples were evaluated in the 9 studies; 596 samples were from early-stage (T1-T2) tumors, and 838 were from late-stage (T3-T4) tumors. FOXC2 was expressed in 46.0% of all samples, in 32.4% of early-stage tumor samples, and in 55.6% of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC2 expression in late-stage samples was 1.367 (95% CI = 1.103-1.695, p = 0.004). Conclusion: The results from our meta-analysis of 9 studies indicate that FOXC2 is 36.7% more likely to be expressed in late-stage tumors than in early-stage tumors.
KW - Cancer
KW - FOXC2
KW - T-Stage
UR - http://www.scopus.com/inward/record.url?scp=85053041972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053041972&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.26087
DO - 10.18632/oncotarget.26087
M3 - Article
C2 - 30279969
AN - SCOPUS:85053041972
SN - 1949-2553
VL - 9
SP - 33396
EP - 33402
JO - Oncotarget
JF - Oncotarget
IS - 70
ER -
